Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.

CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study.

Li G, Sokal I, Quinn JF, Leverenz JB, Brodey M, Schellenberg GD, Kaye JA, Raskind MA, Zhang J, Peskind ER, Montine TJ.

Neurology. 2007 Aug 14;69(7):631-9.

PMID:
17698783
3.

CSF biomarkers for mild cognitive impairment.

Blennow K.

J Intern Med. 2004 Sep;256(3):224-34. Review.

4.

CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: a meta-analysis of 51 studies.

Mitchell AJ.

J Neurol Neurosurg Psychiatry. 2009 Sep;80(9):966-75. doi: 10.1136/jnnp.2008.167791. Epub 2009 May 21. Review.

PMID:
19465413
5.

Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design.

van Rossum IA, Vos S, Handels R, Visser PJ.

J Alzheimers Dis. 2010;20(3):881-91. doi: 10.3233/JAD-2010-091606. Review.

PMID:
20413876
6.

[Diagnosing the mild cognitive impairment stage of Alzheimer's disease].

Maruyama M, Matsui T, Tanji H, Ootsuki M, Nemoto M, Tomita N, Okamura N, Matsushita S, Higuchi S, Kodama M, Arai H, Sasaki H.

Seishin Shinkeigaku Zasshi. 2004;106(3):269-80. Review. Japanese.

PMID:
15164576
7.

[Alzheimer's disease as brain amyloidosis: diagnosis using cerebrospinal fluid abeta and tau].

Shoji M.

Rinsho Byori. 2006 May;54(5):503-8. Review. Japanese.

PMID:
16789421
8.

Amyloid beta protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: a review of recent literature.

Frankfort SV, Tulner LR, van Campen JP, Verbeek MM, Jansen RW, Beijnen JH.

Curr Clin Pharmacol. 2008 May;3(2):123-31. Review.

PMID:
18700307
9.

Cerebrospinal fluid Abeta40 and Abeta42: natural course and clinical usefulness.

Shoji M.

Front Biosci. 2002 Apr 1;7:d997-1006. Review.

PMID:
11897565
10.

Mild cognitive impairment: an opportunity to identify patients at high risk for progression to Alzheimer's disease.

Levey A, Lah J, Goldstein F, Steenland K, Bliwise D.

Clin Ther. 2006 Jul;28(7):991-1001. Review.

PMID:
16990077
11.

Combined biomarkers for early Alzheimer disease diagnosis.

Borroni B, Premi E, Di Luca M, Padovani A.

Curr Med Chem. 2007;14(11):1171-8. Review.

PMID:
17504137
12.

CSF biomarkers for mild cognitive impairment and early Alzheimer's disease.

Andreasen N, Blennow K.

Clin Neurol Neurosurg. 2005 Apr;107(3):165-73. Review.

PMID:
15823670
13.
14.

[MCI-plus: mild cognitive impairment with rapid progression. Part II: Biomarkers and research methods].

Förstl H, Werheid K, Ulm K, Schönknecht P, Schmidt R, Pantel J, Hörr R, Gutzmann H, Gertz HJ, Frölich L, Bickel H.

Dtsch Med Wochenschr. 2009 Jan;134(3):88-91. doi: 10.1055/s-0028-1105896. Epub 2009 Jan 13. Review. German.

PMID:
19142839
15.

Do CSF biomarkers help clinicians predict the progression of mild cognitive impairment to dementia?

Mitchell AJ, Monge-Argilés JA, Sánchez-Paya J.

Pract Neurol. 2010 Aug;10(4):202-7. doi: 10.1136/jnnp.2010.217778. Review.

PMID:
20647526
16.

Biological markers of Alzheimer's disease and mild cognitive impairment.

Maccioni RB, Lavados M, Maccioni CB, Mendoza-Naranjo A.

Curr Alzheimer Res. 2004 Nov;1(4):307-14. Review.

PMID:
15975059
17.

[Clinical heterogeneity in mild cognitive impairment--beyond clinical diagnosis--towards imaging amyloid].

Arai H.

Rinsho Shinkeigaku. 2004 Nov;44(11):924-8. Review. Japanese.

PMID:
15651333
18.

Biological markers in Alzheimer's disease.

Bailey P.

Can J Neurol Sci. 2007 Mar;34 Suppl 1:S72-6. Review.

PMID:
17469687
19.

Predicting Alzheimer dementia in mild cognitive impairment patients. Are biomarkers useful?

Borroni B, Di Luca M, Padovani A.

Eur J Pharmacol. 2006 Sep 1;545(1):73-80. Epub 2006 Jun 16. Review.

PMID:
16831417
20.

[Mild cognitive impairment: a prodromal phase of dementia?].

Jonker C, Comijs HC.

Tijdschr Gerontol Geriatr. 2007 Jul;38(3):115-21. Review. Dutch.

PMID:
17642317

Supplemental Content

Support Center